Review outlines why ALS trials fail and how more personalised treatment could help
Original source
Therapeutic Challenges and Future Breakthroughs in Amyotrophic Lateral Sclerosis: From Precision Medicine to Innovative Trial Design. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
- Studied in
- Human, Animal
A review describes major obstacles in amyotrophic lateral sclerosis (ALS) treatment and drug development, including disease variability, limited biomarkers, weak preclinical models and problems with conventional trial designs. It discusses approaches such as genetic testing, combination treatments and newer trial designs, including adaptive platform trials. The authors argue that more personalised treatment could improve future ALS research and care.
Why this matters
The review may help explain why promising ALS treatments have often failed in late-stage trials and why researchers are moving toward treatments matched to disease subtypes and genetic features. These approaches are still being developed and do not, by themselves, change current treatment for most people with ALS.
Limitations and context
This is a review article, not a new clinical trial or treatment study. Its conclusions depend on previously published evidence, and the proposed strategies still need to demonstrate safety and benefit in well-designed clinical studies. The review also describes a treatment that received accelerated approval and was later voluntarily withdrawn after a confirmatory trial missed its primary endpoints.